Maxim Pharmaceuticals Announces 2005 Second Quarte...

SAN DIEGO, May 02, 2005 (BUSINESS WIRE) — Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM)(SSE:MAXM) today announced results for the quarter ended March 31, 2005, the second quarter of its fiscal year. The net loss applicable to common stock for the quarter totaled $6.6 million or $0.23 per share, compared to a net loss applicable to common stock of $8.9 million or $0.32 per share, for the prior-year quarter. The net loss...

Protagen AG installs new management and board of d...

Dortmund (April 14, 2005) – Protagen closed a first financing round with the VC S-VentureCapital Dortmund for the expansion of its protein biochip business. In the course of this capital influx, positions in the management and the board of directors have been reorganized. Dr. Stefan Muellner has taken over the position of the CSO in the board of Protagen AG. Dr. Muellner brings a lot of experience from positions in...